| scholarly article | Q13442814 |
| P50 | author | Per Ljungman | Q52717443 |
| P2093 | author name string | Hassan M | |
| Ringdén O | |||
| Nilsson C | |||
| Aschan J | |||
| Hentschke P | |||
| P2860 | cites work | A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation | Q31536804 |
| Why metronidazole is active against both bacteria and parasites | Q33676773 | ||
| Clinically significant pharmacokinetic drug interactions with carbamazepine. An update | Q34403438 | ||
| Metronidazole and antipyrine as probes for the study of foreign compound metabolism | Q37918077 | ||
| Venoocclusive disease of the liver following bone marrow transplantation | Q39688572 | ||
| Cytochrome P450 isozymes and antiepileptic drug interactions | Q41112031 | ||
| An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease | Q41734536 | ||
| Pharmacokinetics of liposomal busulphan in man. | Q43583155 | ||
| The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement | Q43659549 | ||
| Metabolism of 14C-busulfan in isolated perfused rat liver | Q43692742 | ||
| Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation | Q43742785 | ||
| Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies | Q43819615 | ||
| Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia | Q44237334 | ||
| Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. | Q51676244 | ||
| [Interstitial pneumopathies caused by busulfan. Histologic, developmental and bronchoalveolar lavage analysis of 3 cases]. | Q52250479 | ||
| Comparison of the sensitivity of human and rat hepatocytes to the genotoxic effects of metronidazole. | Q54324449 | ||
| The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity | Q58789353 | ||
| Metabolism of metronidazole and antipyrine in isolated rat hepatocytes | Q61794888 | ||
| Pharmacokinetic and metabolic studies of high-dose busulphan in adults | Q69665196 | ||
| Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation | Q70806164 | ||
| Gas chromatographic determination of busulfan in plasma with electron-capture detection | Q71104880 | ||
| Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplantation conditioning therapy: a phase I study | Q73171815 | ||
| Binding of 3H-metronidazole in olfactory, respiratory and alimentary epithelia in rats | Q73701022 | ||
| An improved limited sampling method for individualised busulphan dosing in bone marrow transplantation in children | Q73810014 | ||
| Ketobemidone may alter busulfan pharmacokinetics during high-dose therapy | Q74171110 | ||
| Use of a five-agent GVHD prevention regimen in recipients of unrelated donor marrow | Q77780489 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metronidazole | Q169569 |
| pharmacokinetics | Q323936 | ||
| P304 | page(s) | 429-435 | |
| P577 | publication date | 2003-03-01 | |
| P1433 | published in | Bone Marrow Transplantation | Q4941523 |
| P1476 | title | The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation | |
| P478 | volume | 31 |
| Q36659821 | A systematic review on drug interactions in oncology |
| Q46091045 | Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing |
| Q52552920 | Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. |
| Q37334707 | Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. |
| Q42212406 | Clostridium difficile Infection (CDI) in Solid Organ and Hematopoietic Stem Cell Transplant Recipients. |
| Q51016254 | Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions. |
| Q34409335 | Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). |
| Q43122468 | Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers |
| Q37358921 | Effect of weight and maturation on busulfan clearance in infants and small children undergoing hematopoietic cell transplantation |
| Q47116870 | Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. |
| Q46910175 | Individual dose adjustment of oral busulfan using a test dose in hematopoietic stem cell transplantation |
| Q38099040 | Interactions between oral antineoplastic agents and concomitant medication: a systematic review |
| Q84405861 | Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT |
| Q35126138 | Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. |
| Q38068541 | Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation |
| Q36792760 | Variability in the pharmacokinetics of intravenous busulphan given as a single daily dose to paediatric blood or marrow transplant recipients |
| Q100762129 | Vitamin D levels and busulphan kinetics in patients undergoing hematopoietic stem cell transplantation, a multicenter study |
Search more.